Do Current Lung Cancer Screening Guidelines Apply for Populations With High Prevalence of Granulomatous Disease? Results From the First Brazilian Lung Cancer Screening Trial (BRELT1)

Santos, Ricardo S; Franceschini, Juliana; Chate, Rodrigo Caruso; Ghefter, Mário Cláudio; Kay, Fernando Uliana; Trajano, André Luiz C.; Pereira, José Rodrígues; Succi, José Ernesto; Fernando, Hiran C.; Júnior, Roberto Saad

doi:10.1016/j.athoracsur.2015.07.013

Cited by 37 publications

(36 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The baseline detection rate of lung cancer among individuals meeting NLST criteria in our study (2.5%) was higher than other studies, such as NLST (1.0%), 1 NELSON (0.9%) 13 and BRELT1 (1.3%), 14 the latter being the only CT screening study conducted in Brazil, which included patients meeting NLST criteria. One possible explanation for that may be related to the small number of patients at high risk in our study.…”

Section: Discussioncontrasting

confidence: 72%

LDCT lung cancer screening in populations at different risk for lung cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

IntroductionThe improvement of low-dose CT (LDCT) lung cancer screening selection criteria could help to include more individuals who have lung cancer, or in whom lung cancer will develop, while avoiding significant cost increase. We evaluated baseline results of LDCT lung cancer screening in a population with a heterogeneous risk profile for lung cancer.MethodsLDCT lung cancer screening was implemented alongside a preventive health programme in a private hospital in Brazil. Individuals older than 45 years, smokers and former smokers, regardless of tobacco exposure, were included. Patients were classified according to the National Lung Screening Trial (NLST) eligibility criteria and to PLCOm2012 6-year lung cancer risk. Patient characteristics, CT positivity rate, detection rate of lung cancer and false-positive rate were assessed.ResultsLDCT scans of 472 patients were evaluated and three lung adenocarcinomas were diagnosed. CT positivity rate (Lung-RADS 3/4) was significantly higher (p=0.019) in the NLST group (10.1% (95% CI, 5.9% to 16.9%)) than in the non-NLST group (3.6% (95% CI, 2.62% to 4.83%)) and in the PLCOm2012 high-risk group (14.3% (95% CI, 6.8% to 27.7%)) than in the PLCOm2012 low-risk group (3.7% (95% CI, 2.9% to 4.8%)) (p=0.016). Detection rate of lung cancer was also significantly higher (p=0.018) among PLCOm2012 high-risk patients (5.7% (95% CI, 2.5% to 12.6%)) than in the PLCOm2012 low-risk individuals (0.2% (95% CI, 0.1% to 1.1%)). The false-positive rate for NLST criteria (16.4% (95% CI, 13.2% to 20.1%)) was higher (p<0.001) than for PLCOm2012 criteria (7.6 (95% CI, 5.3% to 10.5%)).DiscussionOur study indicates a lower performance when screening low-risk individuals in comparison to screening patients meeting NLST criteria and PLCOm2012 high-risk patients. Also, incorporating PLCOm2012 6-year lung cancer risk ≥0.0151 as an eligibility criterion seems to increase lung cancer screening effectiveness.

show abstract

Section: Discussioncontrasting

confidence: 72%

LDCT lung cancer screening in populations at different risk for lung cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, only 3.1% of the patients required invasive biopsy, similar to other studies. This suggests that the prevalence of granulomatous disease didn't elevate the number of false positive results with a high suspicious for lung cancer, avoiding an unnecessary invasive procedure [13].…”

Section: Editorialmentioning

confidence: 98%

Lung Cancer Prevention in Latin America in the Era of CT Screening

Santos¹,

Franceschini²

2016

Lung Dis Treat

View full text Add to dashboard Cite

“…Sin embargo, sólo 3.1% requirió de una biopsia, resultado similar al de otros ensayos clínicos; ello sugiere que, a pesar de la alta prevalencia de enfermedad granulomatosa, el número de falsos positivos no se elevó. 19 Actualmente, el estudio se encuentra en fase de seguimiento, y se espera que los resultados sean similares. Aproximadamente 60% de los casos nuevos de cáncer se encuentran en países de ingresos medios bajos, como son la mayoría de las naciones latinoamericanas; dos tercios de las muertes por cáncer ocurren en esos países.…”

Section: Artículo Especialunclassified

Detección temprana de cáncer de pulmón en México

2019

View full text Add to dashboard Cite

La detección temprana de cáncer pulmonar (CP) en población de alto riesgo tiene el potencial de diagnosticar la enfermedad en estadios tempranos y facilitar el tratamiento oportuno con el fin de disminuir la tasa de mortalidad. En México, como en otros países en vías de desarrollo, además del tabaquismo, la exposición al humo de leña se posiciona como uno de los principales factores de riesgo para desarrollar CP, lo cual no se ha considerado en estudios de tamizaje previamente publicados. Distintas interrogantes surgen en relación con quiénes son las personas que presentan un alto riesgo de desarrollar CP en América Latina, cuál es el costo-beneficio de poner en marcha un programa de detección oportuna de CP en México y cuáles son los obstáculos que los países de la región enfrentan para su implementación.

show abstract

Do Current Lung Cancer Screening Guidelines Apply for Populations With High Prevalence of Granulomatous Disease? Results From the First Brazilian Lung Cancer Screening Trial (BRELT1)

Cited by 37 publications

References 17 publications

LDCT lung cancer screening in populations at different risk for lung cancer

LDCT lung cancer screening in populations at different risk for lung cancer

Lung Cancer Prevention in Latin America in the Era of CT Screening

Detección temprana de cáncer de pulmón en México

Contact Info

Product

Resources

About